|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US6888027||ACROTECH||Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors|| |
(3 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8835501||ACROTECH||Pharmaceutical formulations of HDAC inhibitors|| |
(4 years from now)
Market Authorisation Date: 03 July, 2014
Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl).
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic